Clinical Trials Logo

Clinical Trial Summary

A clinical study to compare the efficacy and safety of AK105 plus anlotinib and Capecitabine/Oxaliplatin (CapeOx) , anlotinib plus CapeOx, bevacizumab plus CapeOx. A total of 120 cases will be enrolled to the group.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05068206
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Jin Li, Doctor
Phone 13761222111
Email [email protected]
Status Recruiting
Phase Phase 2
Start date October 2021
Completion date June 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04131803 - Probiotics Combined With Standard Chemotherapy Plus Targeted Therapy in Patients With Metastatic Colorectal Cancer N/A
Recruiting NCT03692429 - alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells Phase 1
Not yet recruiting NCT04991948 - Phase 1b Study to Evaluate the Addition of a Pembrolizumab Treatment After Treatment With CYAD-101 With a FOLFOX Preconditioning in Metastatic Colorectal Cancer Patients Phase 1
Completed NCT01802684 - OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer Phase 2
Recruiting NCT04160416 - mXELOXIRI Combined With Molecular Targeted Drug in mCRC Phase 2
Recruiting NCT04866108 - A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy Phase 2